Novartis AG

Strong Financial Performance: Novartis reported a 15% increase in net sales for Q1 2025, with core operating income growing by 27%. The core margin reached 42.1%, and earnings per share were up 31% to $2.28. These figures reflect robust performance across key brands and effective cost management.

Increased Guidance: Due to the strong start in Q1, Novartis has upgraded its full-year sales growth forecast to high single digits (previously mid to high single digits) and core operating income growth to low double digits (previously high single to low double digits). This optimism is driven by exceptional brand performances, including Kisqali and Leqvio.

Opportunities in Pipeline: The company is advancing its innovative drug pipeline with multiple approvals, including Pluvicto for prostate cancer and promising outcomes from gene therapies like OAV-101. Novartis expects these innovations to drive growth into the 2030s, with Pluvicto with a potential peak sales figure of $5 billion and an anticipated positive impact from OAV-101 filings.